Halozyme Therapeutics, Inc. logo HALO - Halozyme Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 17
HOLD 9
SELL 1
STRONG
SELL 0
| PRICE TARGET: $75.00 DETAILS
HIGH: $95.00
LOW: $56.00
MEDIAN: $75.00
CONSENSUS: $75.00
UPSIDE: 9.78%

Profitability Ratios

Ratio Value
GP Margin 78.1%
EBIT Margin 58.4%
EBITDA Margin 64.8%
Operating Margin 58.4%
Pretax Margin 33.4%
Cont. Ops Margin 22.7%
Net Margin 22.7%
Bottom Line Margin 22.7%

Liquidity Ratios

Ratio Value
Current Ratio 4.66
Quick Ratio 3.66
Solvency Ratio 0.164
Cash Ratio 0.76

Valuation Ratios

Ratio Value
Price/Earnings
25.45
Hist. avg: 28.3
Peers avg: 34.3
PEG Ratio -1.04
Forward PEG -1.04
Price/Book 165.22
Price/Sales 5.77
Price/FCF 12.51
Price/Op Cash Flow 12.38

Debt Ratios

Ratio Value
Debt/Assets 0.8485
Debt/Equity 43.8938
Debt/Capital 0.9777
Long-Term Debt/Capital 0.9777
Financial Leverage 51.73

Cash Flow Ratios

Ratio Value
Working Capital Turnover 1.75
Operating Cash Flow Ratio 3.679
Operating Cash Flow/Sales 46.7%
Free Cash Flow/Operating Cash Flow 98.9%

Coverage Ratios

Ratio Value
Debt Service Coverage 41.62
Interest Coverage 45.0344
Short-Term Operating Cash Flow Coverage 0.00
Operating Cash Flow Coverage 0.30
Capital Expenditure Coverage 93.48
Dividend + Capital Expenditure Coverage 93.48

Dividend Ratios

Ratio Value
Payout Ratio 0.0000%
Dividend Yield 0.0000%
Dividend Yield % 0.0000%
Dividend Per Share 0.0000

Per Share Ratios

Ratio Value
Revenue/Share 11.65
EPS 2.644
Debt/Share 18.0303
Cash/Share 1.19
Book Value/Share 0.41
Tangible BV/Share -12.63
Equity/Share 0.41
Operating Cash Flow/Share 5.437
Capital Expenditure/Share 0.058
FCF/Share 5.379

Other Ratios

Ratio Value
Net Income/Earnings Before Tax 0.679
Earnings Before Tax/EBIT 0.572
Price/Fair Value 165.22
Debt/Market Cap 0.2657
Effective Tax Rate 32.1%
Enterprise Value Multiple 11.14